The aim of this project is to develop an innovative, highly efficient assay for detecting genes that may be functionally important in cancer. There are a number of challenges to detecting such genes, including the extensive mutation and rearrangement of the cancer genome; the variety of molecular mechanisms which can go awry, leading to extensive molecular variation between cancers; and the heterogeneity of cancer samples, which tend to include a mixture of cell types, both normal and abnormal. Our strategy for detecting cancer causing genes is to apply microarray concepts to enable a high-throughput genome-wide screening approach that will help overcome some of the challenges due to molecular and cellular heterogeneity. In the first phase of the project, we intend to develop a simple model system for assay development by constructing plasmid clones and using synthetic oligonucleotides specific for a small number of genes. In Phase II, we will expand the assay system to include a large set of genes, and we will validate the assay system using actual cancer samples and controls. We expect that, once developed, our approach will allow many samples to be screened at a high resolution, rapidly, reliably and cost- effectively. Our approach may enable the discovery of new genes that play an important role in cancer. Some genes that help transform normal cells into cancerous ones have proven to be good targets for the development of more effective cancer drugs. However, much remains to be discovered about such genes and the mechanisms by which they act. This proposal is aimed at developing a powerful and efficient new way to find important cancer genes, which may lead to a better understanding of the disease and improved tests and treatments. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Human Genome Research Institute (NHGRI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
1R44HG004237-01
Application #
7163228
Study Section
Special Emphasis Panel (ZRG1-GGG-J (10))
Program Officer
Ozenberger, Bradley
Project Start
2006-09-25
Project End
2007-02-28
Budget Start
2006-09-25
Budget End
2007-02-28
Support Year
1
Fiscal Year
2006
Total Cost
$99,847
Indirect Cost
Name
Prognosys Biosciences, Inc.
Department
Type
DUNS #
170943737
City
La Jolla
State
CA
Country
United States
Zip Code
92121
Pflueger, Dorothee; Terry, Stéphane; Sboner, Andrea et al. (2011) Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Res 21:56-67
Sboner, Andrea; Habegger, Lukas; Pflueger, Dorothee et al. (2010) FusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data. Genome Biol 11:R104
Pflueger, Dorothee; Rickman, David S; Sboner, Andrea et al. (2009) N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia 11:804-11